News
RCM calls for urgent investment in perinatal mental health support
The Royal College of Midwives (RCM) is calling for urgent investment in perinatal mental health support – not only in services, but also the midwives that provide them.
Low mood and poor mental health affect many people, but during the perinatal period women can be particularly vulnerable. Pregnancy is often portrayed as a time of great happiness, but for many women it can be anything but, as they cope with the huge adjustment to their lives becoming a parent entails. It can be a time when women need the most support with their mental health.
During pregnancy and up to one year after birth, one in five women will experience mental health issues, ranging from anxiety and depression to more severe illness and in the worst cases lead to suicide. Suicide remains one of the leading causes of death in new mothers.
The RCM has long raised the need for better perinatal mental health support, with investment not only in services, but also the midwives that provide them.
The RCM is also supporting the Maternal Mental Health Alliance’s (MMHA) Everyone’s Business campaign which calls for calls for all women across the UK to receive the mental health care they and their families need during pregnancy and postnatally.
RCM chief executive, Gill Walton, said: “The RCM has long campaigned for better mental health support for women throughout pregnancy and in the postnatal period. Demand often outstrips supply when it comes to perinatal mental health support, so there needs to be better investment in support for pregnant women and new mothers.
“Many of us think of new parenthood as a happy time, but for many women and families the strain can have a profound impact on their mental health. Tragically, suicide continues to be one of the most common causes of maternal death. Making sure that women have access to good, appropriate mental health support, both during and immediately following pregnancy, is vital.”
The RCM says action is needed to develop more and better support for women, which is why, in 2023, it published a landmark perinatal mental health road map, a set of guiding principles for perinatal mental health services which was widely welcomed by midwifery leaders.
If these recommendations are followed, it can lead to improved mental healthcare for pregnant women and new mothers in the UK.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






